Cenric Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-07-2024
- Paid Up Capital ₹ 5.00 K
as on 24-07-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -56.96%
(FY 2023)
- Profit -165.07%
(FY 2023)
- Ebitda -165.07%
(FY 2023)
- Net Worth -1.67%
(FY 2023)
- Total Assets 277.78%
(FY 2023)
About Cenric Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 5.00 K , as per Ministry of Corporate Affairs (MCA) records.
Apurba Purkayastha and Abhishek Purkayastha serve as directors at the Company.
- CIN/LLPIN
U24304AS2019PTC019245
- Company No.
019245
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 May 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Silchar, Assam, India
- Telephone
- Email Address
- Website
-
- Social Media
What products or services does Cenric Pharmaceuticals Private Limited offer?
Cenric Pharmaceuticals Private Limited offers a wide range of products and services, including Diamonds & Diamond Jewels, Diamond Bangles, Precious Stones and Gemstones, Semi Precious Stones, Natural Diamond, Cleaning Liquids & Wipes, Cleaning Chemicals, Industrial Chemicals & Supplies, Industrial Salts, Chemical Reagents & Catalysts.
Who are the key members and board of directors at Cenric Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Apurba Purkayastha  | Director | 23-May-2019 | Current |
| Abhishek Purkayastha | Director | 23-May-2019 | Current |
Financial Performance of Cenric Pharmaceuticals.
Cenric Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 56.96% decrease. The company also saw a substantial fall in profitability, with a 165.07% decrease in profit. The company's net worth dipped by a decrease of 1.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cenric Pharmaceuticals?
In 2023, Cenric Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cenric Pharmaceuticals?
Unlock and access historical data on people associated with Cenric Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cenric Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cenric Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
